First Horizon Advisors, Inc. Travere Therapeutics, Inc. Transaction History
First Horizon Advisors, Inc.
- $3.55 Billion
- Q4 2024
A detailed history of First Horizon Advisors, Inc. transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, First Horizon Advisors, Inc. holds 285 shares of TVTX stock, worth $6,198. This represents 0.0% of its overall portfolio holdings.
Number of Shares
285Holding current value
$6,198% of portfolio
0.0%Shares
5 transactions
Others Institutions Holding TVTX
# of Institutions
203Shares Held
85.2MCall Options Held
776KPut Options Held
912K-
Armistice Capital, LLC New York, NY7.65MShares$166 Million1.78% of portfolio
-
Black Rock Inc. New York, NY7.64MShares$166 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.9MShares$150 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD4.68MShares$102 Million2.23% of portfolio
-
Woodline Partners LP San Francisco, CA4.34MShares$94.4 Million0.55% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $1.4B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...